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Efﬁcacy and safety of deferasirox doses of >30 mg/kg per d in
patients with transfusion-dependent anaemia and iron overload
Deferasirox (Exjade
 ) is a once-daily oral iron chelator
approved for the treatment of transfusional iron overload in
patients with transfusion-dependent anaemia. During a com-
prehensive series of 1-year core (Cappellini et al, 2006;
Galanello et al, 2006; Piga et al, 2006; Vichinsky et al, 2007;
Porter et al, 2008; Taher et al, 2009) and ongoing (Porter et al,
2007) extension trials, deferasirox was evaluated at starting
doses ranging from 5 to 30 mg/kg per d, with maintenance
doses of up to 40 mg/kg per d in the extension trials. The
efﬁcacy of deferasirox was primarily evaluated based on the
assessment of serum ferritin, which remains the most widely
used method for evaluating body iron burden. The measure-
ment of serum ferritin is convenient and inexpensive, and
serial measurements provide a relatively robust marker of iron
burden; signiﬁcant correlations between changes in serum
ferritin and liver iron concentration (LIC) have been identiﬁed
across various underlying anaemias (Cappellini et al, 2006;
Porter et al, 2008). Current guidelines for assessing iron
burden and monitoring the efﬁcacy of chelation therapy
recommend the use of serum ferritin (Thalassaemia Interna-
tional Federation, 2008).
Pharmacological studies have shown that the pharmaco-
kinetics of orally administered deferasirox at doses of 10, 20
and 40 mg/kg per d is linear and drug exposure is dose
proportional in patients at steady state (Nisbet-Brown et al,
2003). In addition, across the clinical trial programme,
response to deferasirox was shown to be dependent on dose.
A subsequent analysis based on data from a single study
highlighted the additional impact of transfusional iron intake
on response (Cohen et al, 2008). In this analysis 47%, 55% and
75% of patients in the high (>0Æ5 mg/kg per d), intermediate
(0Æ3–0Æ5 mg/kg per d) and low (<0Æ3 mg/kg per d) iron intake
categories respectively, achieved a reduction in LIC with
20 mg/kg per d, while the equivalent proportions at a dose of
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Summary
The highest approved dose of deferasirox is currently 30 mg/kg per d in many
countries; however, some patients require escalation above 30 mg/kg per d to
achieve their therapeutic goals. This retrospective analysis investigated the
efﬁcacy (based on change in serum ferritin levels) and safety of deferasirox
>30 mg/kg per d in adult and paediatric patients with transfusion-dependent
anaemias, including b-thalassaemia, sickle cell disease and the
myelodysplastic syndromes. In total, 264 patients pooled from four clinical
trials received doses of >30 mg/kg per d; median exposure to deferasirox
>30 mg/kg per d was 36 weeks. In the overall population there was a
statistically signiﬁcant median decrease in serum ferritin of 440 lg/l
(P <0 Æ0001) from pre-dose-escalation to the time-of-analysis; signiﬁcant
decreases were also observed in adult and paediatric patients, as well as
b-thalassaemia patients. The adverse event proﬁle in patients who received
deferasirox doses of >30 mg/kg per d was consistent with previously
published data. There was no worsening of renal or liver function following
dose escalation. Deferasirox >30 mg/kg per d effectively reduced iron burden
to levels lower than those achieved prior to dose escalation in patients with
transfusion-dependent anaemias. This has important implications for
patients who are heavily transfused and may require higher doses to reduce
body iron burden.
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Therefore it is clear that some patients require dose escalation
to >30 mg/kg per d in order to achieve their therapeutic goals,
i.e. to have a sufﬁciently rapid decrease of iron burden in
heavily iron-overloaded patients, or to successfully prevent
iron accumulation in patients with acceptable iron burden
levels.
However, when deferasirox was ﬁrst licensed in 2005, there
was a comparatively small clinical database and a limited
number of patients had been exposed to doses of >30 mg/kg
per d. As such, doses above 30 mg/kg per d were not
recommended in the prescribing information for deferasirox
when the drug was ﬁrst approved. As a larger number of
patients have now been exposed to deferasirox doses of
>30 mg/kg per d for a prolonged period of time, a retrospec-
tive analysis has been performed to investigate the efﬁcacy and
safety of such doses. Data for this analysis have been pooled
from four prospective clinical trials in patients with various
transfusion-dependent anaemias, including b-thalassaemia,
sickle cell disease (SCD) and the myelodysplastic syndromes
(MDS).
Methods
Eligibility criteria
Male or female patients aged ‡2 years with transfusional iron
overload, as deﬁned by a LIC of ‡2 mg Fe/g dry weight (dw) at
the start of deferasirox treatment, were eligible for inclusion in
this analysis. All patients were required to have baseline serum
creatinine levels below the upper limit of normal (ULN) and
were excluded if alanine aminotransferase (ALT) levels were
>250 U/l in the previous year. More detailed enrolment
criteria for the four studies have been published elsewhere
(Cappellini et al, 2006; Vichinsky et al, 2007; Porter et al,
2008; Taher et al, 2009).
Institutional Review Board or Ethics Committee approval
was obtained at each participating institution. All patients (or
parents/guardians) provided written informed consent. All
studies were conducted in accordance with Good Clinical
Practice guidelines and the Declaration of Helsinki and were
closely monitored by Novartis personnel or a contract
organization for compliance to the protocols and the proce-
dures described in them.
Study design and dosing
This pooled analysis was performed using data from the core
and ongoing extension phases of four prospective multicentre,
open-label trials in patients who received deferasirox >30 mg/
kg per d (Cappellini et al, 2006; Vichinsky et al, 2007; Porter
et al, 2008; Taher et al, 2009); a summary of these trials is
provided in Table I. All four trials used comparable efﬁcacy and
safety monitoring and assessment methods and are therefore
suitable for pooled analysis.
Initial deferasirox doses in studies 1–3 were 5–30 mg/kg
per d, depending on baseline LIC; doses above 30 mg/kg per d
were not permitted (Cappellini et al, 2006; Vichinsky et al,
2007; Porter et al, 2008). In the extension studies, investigators
were allowed to increase the doses above 30 mg/kg per d up to
40 mg/kg per d in patients in whom the control of body iron
was judged inadequate after review/approval by the Safety
Monitoring Committee. Dose increases in steps of 5–10 mg/kg
per d were recommended after a minimum of 3 months’
treatment for patients with baseline serum ferritin of >500 lg/l
who had an increasing serum ferritin trend, or for those with
baseline serum ferritin of >1000 lg/l who did not have a
serum ferritin decrease.
During the 1-year core phase of study 4, all patients started
on deferasirox 20 mg/kg per d except three who started on
10 mg/kg per d (Taher et al, 2009). Doses of >30 mg/kg per d
were not initially recommended in the extension study,
although this was subsequently changed following a protocol
amendment. Dose increases of 5–10 mg/kg per d were
recommended for patients who had conﬁrmed rises in serum
ferritin of ‡1000 lg/l above baseline, or for patients whose
serum ferritin remained at >2500 lg/l without showing a
downward trend.
Assessments
Efﬁcacy was assessed based on the monthly serum ferritin
observations before and after escalation to doses of >30 mg/kg
per d.
Safety was evaluated throughout treatment after escalation
to doses of >30 mg/kg per d, based on the incidence and type
of adverse events (AEs) and serious AEs, and routine
laboratory testing including serum creatinine and liver enzyme
levels.
Patient populations and statistical methods
To evaluate patients who were intended to receive deferasirox
>30 mg/kg per d and to avoid variability based on tablet
strength (as some patients may have unintentionally received
doses of >30 mg/kg per d due to the fact that the only tablet
strengths available are 125, 250 or 500 mg), only patients with
a prescribed dose of >30 mg/kg per d and an actual daily dose
of ‡32Æ5 mg/kg per d were analysed. The term ‘doses of
>30 mg/kg per d’ used in the subsequent text is deﬁned based
on these two criteria.
All efﬁcacy analyses are based on patients treated with doses
of >30 mg/kg per d, as deﬁned previously, and who had serum
ferritin assessments at study baseline and at least once after
escalation to doses of >30 mg/kg per d. All safety analyses are
based on patients treated with doses of >30 mg/kg per d who
had at least one safety assessment performed after escalation to
doses of >30 mg/kg per d. Transfusional iron intake was
calculated according to the method previously described by
Cohen et al (2008).
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ing the observed values over 3-month periods. The reference
point prior to dose escalation was calculated by averaging the
observed values over the previous 3 months. Data were mainly
summarized descriptively. Graphical representations were also
used to follow change over time; the boxes in Figs 1 and 2
display the 10th and the 90th percentiles and the medians are
connected. The last observed serum ferritin value was
compared to pre-dose escalation values using paired Wilcoxon
tests when the number of patients with both a pre-dose
escalation and post-dose escalation value was >10.
Results
Patient characteristics
Of 1176 patients who received deferasirox across the four
studies,264(22Æ4%)receiveddosesof>30 mg/kgperd.Mostof
these 264 patients had their doses escalated due to inadequate
control of serum ferritin levels. This population was composed
primarily of patients with b-thalassaemia (Table II). Median
serum ferritin levels at pre-dose escalation in paediatric and
adult patients were 3843 and 3930 lg/l, respectively.
Table I. Summary of trials included in this analysis.
Novartis trial
number Design Patient population
Patients exposed
to deferasirox
Patients
contributing to
this analysis, n (%)
CICL670A0107E (Study 1)
Cappellini et al (2006)
Randomized, comparative
deferasirox versus DFO
(1 year), followed by deferasirox
only (4 years)
Adult and paediatric
patients with b-thalassaemia
major
555 99 (17Æ8)
CICL670A0108E (Study 2)
Porter et al (2008)
Single arm of deferasirox,
non-comparative
Adult and paediatric patients
with MDS, DBA and other
anaemias of diverse aetiologies
184 34 (18Æ5)
CICL670A0109E (Study 3)
Vichinsky et al (2007)
Randomized, comparative
deferasirox versus DFO (1 year),
followed by deferasirox
only (4 years)
Adult and paediatric patients
with SCD
185 32 (17Æ3)
CICL670A02402E (Study 4)
Taher et al (2009)
Single arm of deferasirox,
non-comparative
Adult and paediatric patients
with b-thalassaemia major
237* 99 (41Æ8)
DFO, deferoxamine; MDS, myelodysplastic syndromes; DBA, Diamond-Blackfan anaemia; SCD, sickle cell disease.
*Fifteen patients from a single site were excluded from the ﬁnal analysis because routine monitoring of study documents at the site could not conﬁrm
the accuracy of the data reported (Taher et al, 2009).
Fig 1. Relative change (%) in serum ferritin levels from pre-dose escalation (efﬁcacy population). Note: The boxes represent the 25th and 75th
percentiles, while the whiskers correspond to the 10th and 90th percentiles. The medians are connected.
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Forthe264patientswhohadtheirdosesescalatedto>30 mg/kg
per d, overall median transfusional iron intake was 0Æ34 mg/kg
per d for the 6 months preceding dose escalation, which
remained constant once doses had been escalated.
Deferasirox dosing
After dose escalation, 33 patients (12Æ5%) received an average
deferasirox dose of <32Æ5 mg/kg per d, 98 patients (37Æ1%) an
average dose of ‡32Æ5 to <37Æ5 mg/kg per d, 130 patients
(49Æ2%) an average dose of ‡37Æ5 to <42Æ5 mg/kg per d and
three patients (1Æ1%) an average dose of ‡42Æ5 mg/kg per d.
Overall median exposure to deferasirox was 169 weeks, while
median exposure from the ﬁrst to last administration of
deferasirox >30 mg/kg per d was 36 weeks. The median of the
last dose prior to escalation was 30Æ0 mg/kg per d, while the
median dose after escalation was 37Æ5 mg/kg per d. Twenty-six
patients (9Æ8%) had 32 dose reductions, primarily decreases
according to the study protocol (e.g. body weight change),
while 101 patients (38Æ2%) had drug interruptions, mostly
because of missed doses. The median duration of drug
interruption was 2 d (range 1–152).
Change in serum ferritin levels
Overall, 261 patients (98Æ9%) met the requirements for the
efﬁcacy analysis. Pre-escalation serum ferritin levels ranged
from c. 3500 to 4500 lg/l across all underlying anaemias
(Table III). In this efﬁcacy population, the median relative
change in serum ferritin at the time-of-analysis was )12Æ8%
compared with the level preceding dose escalation to
>30 mg/kg per d (Fig 1; Table III). In these patients there
was a statistically signiﬁcant median decrease in serum ferritin
of 440 lg/l (P <0 Æ0001; Table III) from pre-dose-escalation to
the time-of-analysis.
In patients with b-thalassaemia, deferasirox doses of
>30 mg/kg per d signiﬁcantly reduced serum ferritin at the
Table II. Patient characteristics prior to dose escalation.
Variable >30 mg/kg per d (n = 264)
Mean age ± SD, years 19Æ0±8 Æ4
Median (range) 17Æ7 (5–53)
Age, n (%)
<16 years 113 (42Æ8)
‡16 years 151 (57Æ2)
Male:female 129:135
Race, n (%)
Caucasian 138 (52Æ3)
Black 28 (10Æ6)
Oriental 56 (21Æ2)
Other 42 (15Æ9)
Underlying anaemia, n (%)
b-thalassaemia 225 (85Æ2)
MDS –
DBA/rare anaemias 7 (2Æ7)
SCD 32 (12Æ1)
Median serum ferritin (range), lg/l
Start of deferasirox treatment 3937 (342–25 008)
Pre-dose escalation 3880 (876–15 747)
MDS, myelodysplastic syndromes; DBA, Diamond-Blackfan anaemia;
SCD, sickle cell disease.
Fig 2. Serum creatinine levels before and after dose escalation to doses >30 mg/kg per d (safety population). Note: The boxes represent the 25th and
75th percentiles, while the whiskers correspond to the 10th and 90th percentiles. The medians are connected.
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by 487 lg/l (P <0 Æ0001; Table III). In patients with SCD,
median serum ferritin levels decreased by 193 lg/l. In paedi-
atric patients (aged <16 years), dose escalation to >30 mg/kg
per d signiﬁcantly reduced serum ferritin levels by 617 lg/l
compared to the levels prior to dose escalation (P <0 Æ0001,
n = 111; Table III). Similarly, doses of >30 mg/kg per d also
provided signiﬁcant reductions in serum ferritin levels by
368 lg/l in adult patients (P =0 Æ001, n = 150). There was no
signiﬁcant difference between paediatric and adult patients
with respect to the relative median change in serum ferritin
from pre-escalation to last observed assessment ()15Æ2 vs.
)11Æ6; P =0 Æ1984).
Safety and tolerability
Forty-nine (18Æ6%) patients had AEs leading to either dose
reduction or drug interruption (45 patients had drug inter-
ruption, three patients had dose reduction and one patient had
both). Median dose prior to interruption was 37Æ4 mg/kg per
d, while median dose prior to reduction was 35 mg/kg per d.
Thirty-two of these 49 patients continued treatment with
deferasirox until the completion of the study. Of the remaining
17 patients, nine patients still were treated with deferasirox at
the cut-off date of this pooled analysis, three patients
discontinued the study due to unsatisfactory therapeutic effect
as assessed by the investigator, two patients discontinued due
to AEs (see section below), two patients withdrew consent, and
one patient was lost to follow-up.
Study discontinuations. At the time of analysis 32 patients
(12Æ1%) were still on study, while 185 (70Æ1%) had completed
the extension studies. Forty-seven dose-escalated patients
(17Æ8%) permanently discontinued due to: insufﬁcient change
in serum ferritin as assessed by the investigator (n = 19), AEs
(n = 10),consentwithdrawal(n = 10),losttofollow-up(n = 4),
abnormal laboratory values (n = 3) and administrative
problems (n = 1). The AEs leading to discontinuation were
increased ALT, lenticular opacities (classed as a serious AE),
increased serum ferritin, cardiac failure in two patients
(serious AEs), abdominal discomfort, hypotension (serious
AE), dyspnoea (serious AE), gastrointestinal haemorrhage
(serious AE)and marrowtransplantation due to b-thalassaemia
(serious AE). Four of the 10 AEs resulting in discontinuation
(lenticular opacities, increased serum ferritin, abdominal
discomfort, gastrointestinal haemorrhage) were suspected by
the investigators to be drug-related. Median dose prior to
discontinuation was 39Æ5 mg/kg per d; the median time
between study discontinuation and the last dose was 1 d (range
)1to 95).
Adverse events. Overall, 237 (89Æ8%) and 173 (65Æ5%) patients
experienced an AE before and after escalation to >30 mg/kg
per d, respectively. Most AEs were mild to moderate in nature.
Ten patients (3Æ8%) only had AEs after dose escalation, three
of whom received doses >30 mg/kg per d at baseline; nine had
baseline serum ferritin levels >1000 lg/l.
Table III. Median of relative and absolute change in serum ferritin at last observed assessment following dose escalation to >30 mg/kg per d, by
subgroup (efﬁcacy population).
Population n*
Pre-escalation serum
ferritin (range), lg/l
Relative change
from pre-escalation, %
Absolute change from
pre-escalation, lg/l [95% CI] P-value 
All patients 261 3880 (876–15 747) )12Æ8 )440 [)618, )286] <0Æ0001
b-thalassaemia 222 3794 (876–15 747) )14Æ2 )487 [)624, )286] <0Æ0001
SCD 32 4516 (1355–11 288) )5Æ8 )193 [)724, 259] ns
DBA/rare anaemias 7 3469 (1141–12 290) )27Æ9 )923 [)1610, 579] –
Adults 150 3930 (1141–15 747) )11Æ6 )368 [)568, )160] 0Æ001
Paediatrics 111 3843 (876–8511) )15Æ2 )617 [)839, )289] <0Æ0001
DBA, Diamond-Blackfan anaemia; SCD, sickle cell disease; CI, conﬁdence intervals; ns, non-signiﬁcant.
*Patients with available pre- and post-escalation serum ferritin levels.
 P-value based on paired Wilcoxon test, absolute serum ferritin change versus pre-escalation.
Table IV. Number (%) of patients with drug-related adverse events as
assessed by investigators (observed in >1 patient after dose escalation
to >30 mg/kg per d).
AE
Frequency, n (%)
Before dose
escalation
After dose
escalation
Total exposure (patient years) 631Æ6 273Æ4
ALT increase* 13 (4Æ9) 8 (3Æ0)
Vomiting 19 (7Æ2) 7 (2Æ7)
Nausea 26 (9Æ8) 5 (1Æ9)
Abdominal pain 17 (6Æ4) 4 (1Æ5)
Upper abdominal pain 4 (1Æ5) 4 (1Æ5)
Blood creatinine increase* 22 (8Æ3) 3 (1Æ1)
Abdominal discomfort 2 (0Æ8) 2 (0Æ8)
Diarrhoea 16 (6Æ1) 2 (0Æ8)
AST increase* 6 (2Æ3) 2 (0Æ8)
Transaminase increase* 5 (1Æ9) 2 (0Æ8)
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
*Reported as an AE by the investigator.
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tor-assessed) AE after dose escalation to >30 mg/kg per d. The
most common drug-related AEs before and after escalation are
shown in Table IV. Of the eight patients who had an ALT
increase after dose escalation, two had the same AE before dose
escalation and four had elevated ALT before receiving defer-
asirox. None of the three patients who had a serum creatinine
increase after dose escalation had this AE before escalation.
Forty-two patients (15Æ9%) had a serious AE following
escalation to >30 mg/kg per d; those assessed as possibly drug-
related were lenticular opacities, increased transaminases,
gastrointestinal haemorrhage, abdominal pain and abnormal
liver function tests (n = 1 for each). After escalation there
were no cases of pancreatitis or obstructive jaundice, one
(0Æ4%) case of gastritis, one (0Æ4%) case of cholecystitis and ﬁve
(1Æ9%) cases of cholelithiasis; no cases of gastritis, cholecystitis
or cholelithiasis were considered to be drug-related. There were
no deaths among patients who received doses of >30 mg/kg
per d.
Renal parameters. After escalation to >30 mg/kg per d, the
median of relative change in serum creatinine remained
unchanged at the end-of-study compared with pre-escalation
(Fig 2). Two patients (0Æ8%) had serum creatinine above the
ULN, at two consecutive assessments more than 7 d apart after
dose escalation. One of them had normal serum creatinine
levels prior to dose escalation. One patient had a urine
protein:creatinine (UPUC) ratio >1Æ0 mg/mg at two
consecutive visits after escalation to >30 mg/kg per d. Eight
patients (3Æ0%) had a UPUC ratio >1Æ0 mg/mg at one visit,
seven of whom had a normal UPUC ratio prior to dose
escalation. Twenty-seven patients (10Æ2%) had one episode of
abnormal UPUC ratio <1Æ0 mg/mg, 18 of whom had a normal
ratio prior to dose escalation.
Hepatic safety. Nine patients (3Æ4%) had ALT levels of
>5 · ULN but <10 · ULN at two consecutive assessments at
least 7 d apart, all of whom had ALT >ULN prior to escalation
to doses >30 mg/kg per d. Three patients, two of whom who
had ALT < ULN prior to dose escalation, had ALT values of
>10 · ULN at two consecutive visits after escalation.
Auditory and ophthalmic assessments. One patient, who
permanently discontinued treatment, had a lenticular opacity
assessed as drug-related after escalation to doses of >30 mg/kg
per d (39 mg/kg per d); this patient had a normal eye
examination at baseline. Six additional patients had ocular
abnormalities suggestive of impaired vision (four patients
with blurred vision and one each with reduced visual acuity
and papilloedema) reported after dose escalation; none were
assessed as drug related by the investigator. In 2/7 patients who
had an ocular AE of interest, ophthalmological examination
revealed normal (n = 1) or clinically insigniﬁcant (n =1 )
results at the onset of the AE. The lenticular opacity
experienced by one patient was detected by ophthalmologic
examination. In two of the remaining four patients, the AEs
were preceded and followed by normal ophthalmological
examinations. Ophthalmological examinations were not
available in the remaining two patients. Four patients reported
some hearing loss after dose escalation to >30 mg/kg per d,
although none discontinued and one already had hearing loss
on lower deferasirox doses. One of these episodes was assessed
as drug related.
Discussion
Previous studies have indicated that some patients require
deferasirox doses of >30 mg/kg per d in order to achieve their
therapeutic goals. Here we report for the ﬁrst time that such
doses are effective with a comparable safety proﬁle to doses of
<30 mg/kg per d. The patients who were escalated to doses of
>30 mg/kg per d presented with very high median serum
ferritin levels prior to escalation (3880 lg/l overall); 208
patients (78Æ8%) had levels >2500 lg/l, which has been
associated with an increased risk of iron overload-related
complications (Olivieri et al, 1994; Olivieri & Brittenham,
1997) and shown to require intensiﬁcation of chelation therapy
(Thalassaemia International Federation, 2008).
Despite limited exposure (median 36 weeks), this analysis
demonstrates that escalation of deferasirox to doses of
>30 mg/kg per d effectively decreased serum ferritin compared
with levels prior to dose escalation in patients whose serum
ferritin levels were not adequately controlled before escalation.
The serum ferritin decreases were signiﬁcant in the overall
population, in adult and paediatric patients, as well as patients
with b-thalassaemia. Although patients with SCD and other
anaemias were included in this analysis, the patient numbers
were too low to provide any meaningful information. This may
suggest that iron overload in these populations was sufﬁciently
well managed on deferasirox doses of £30 mg/kg per d and
they generally did not require escalation to >30 mg/kg per d.
However, more than half of the SCD patients (n = 18, 56%)
had drug interruptions (‡4 in 78% of patients) after dose
escalation, which may have impacted on the serum ferritin
response. It is also worth noting that the measurement of
serum ferritin levels is a less reliable marker of iron overload in
SCD than in other anaemias. This is because ferritin is an acute
phase reactant therefore levels can be greatly inﬂuenced by
inﬂammation (Brownell et al, 1986), which is an important
factor in the pathophysiology of SCD.
Patients who required escalation to doses of >30 mg/kg
per d were heavily iron overloaded, which was reﬂected by
high serum ferritin levels at baseline. These patients also
received an intermediate amount of transfusional iron intake
(7–14 ml/kg per month) after dose escalation. This empha-
sizes the need to dose deferasirox based on goal of therapy,
iron burden and transfusional iron intake, and highlights that
dose escalation may be required in patients with severe iron
overload who do not respond sufﬁciently to doses up to
30 mg/kg per d.
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deferasirox doses of >30 mg/kg per d was consistent with that
observed in the 1-year core trials (Cappellini et al, 2006;
Galanello et al, 2006; Piga et al, 2006; Vichinsky et al, 2007;
Porter et al, 2008). Importantly, there were no AEs observed
following escalation to >30 mg/kg per d that were not
observed at lower doses before escalation. Serum creatinine
levels remained unchanged at the end of study period
compared with the pre-escalation level, which suggests that
the risk of impaired renal function is low while administering
doses of >30 mg/kg per d in heavily iron-overloaded patients.
Forty-two patients experienced a serious AE following dose
escalation to >30 mg/kg per d, which was consistent with those
observed prior to dose escalation and in the 1-year core trials
(Cappellini et al, 2006; Galanello et al, 2006; Piga et al, 2006;
Vichinsky et al, 2007; Porter et al, 2008; Taher et al, 2009) and
typical of those expected in the target population. The safety of
doses >30 mg/kg per d was not assessed in patients with serum
ferritin levels £1000 lg/l as only one patient had such low
levels at dose escalation. It is therefore not possible to
comment on the safety of doses >30 mg/kg per d in patients
with low levels of iron loading. However, in general, high doses
should be reserved for patients with very high levels of iron
loading who are not responding to doses <30 mg/kg per d.
Limitations of this study include the fact that it was a
retrospective analysis and patients who were included were
likely to be those who tolerated doses <30 mg/kg per d, which
is important to consider when reviewing the safety data.
In conclusion, these ﬁndings indicate that escalation of
deferasirox doses to >30 mg/kg per d effectively reduces iron
burden to lower levels than those achieved prior to dose
escalation, without an increase in the incidence of AEs or a
worsening of renal or liver function. Deferasirox dose should
be titrated to meet individual patient needs as dictated by
transfusional iron intake and the goal of therapy (reduction or
maintenance of body iron stores). Before considering dose
escalation to >30 mg/kg per d to reduce body iron burden in
patients with severe iron overload, it is important to assess
both the response to therapy (serum ferritin monitoring) and
compliance at doses £30 mg/kg per d. The dose-escalated
patients should be regularly monitored and, once body iron
stores fall into an acceptable range, deferasirox dose should be
decreased to an appropriate maintenance level.
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